IMUX News and Press, Immunic Inc. From 03/04/24

2024-03-04 09:30:00 ET March 4, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the AI (artificial intelligence) Tech and Biotech sectors. The newest tech companies are all invo...

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 PR Newswire NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipelin...

2024-02-22 15:38:13 ET Immunic, Inc. (IMUX) Q4 2023 Earnings Conference Call February 22, 2024, 8:00 AM ET Company Participants Jessica Breu - Vice President, Investor Relations and Communications Daniel Vitt - Chief Executive Officer, President and Director Glen...

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on February 22, 2024 – NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Immunic...

2024-02-13 16:45:29 ET More on Immunic Immunic announces private placement of up to $240 million Seeking Alpha’s Quant Rating on Immunic Read the full article on Seeking Alpha For further details see: Immunic files to sell 55.94M shares for its hol...

Immunic to Participate in Investor and Scientific Conferences in February PR Newswire NEW YORK , Feb. 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ...

2024-01-05 10:07:14 ET DENVER, Colo., Jan. 5, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Banzai International Inc (NASDAQ: BNZI), Immunic Inc (NASDAQ: IMUX), Dermata Therapeutics (NASDAQ: DRMA), Aino...

2024-01-05 06:39:23 ET More on Immunic Immunic, Inc. (IMUX) Q3 2023 Earnings Call Transcript Immunic: Latest CALLIPER Data Reinforces Vidofludimus Calcium For Multiple Sclerosis Immunic jumps after the bell on positive interim data from phase 2 CALLIPER trial ...

Immunic Highlights 2023 Accomplishments and Upcoming Milestones PR Newswire – Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis , Consistent Across the Entire Progressive Multiple Sclerosis Population and All S...

Immunic, Inc. Announces Private Placement of up to $240 Million PR Newswire NEW YORK , Jan. 5, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a biotechnology company developing a clinical pipeline of orally administered, s...